Labcorp Holdings Inc. $LH Shares Acquired by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ lifted its position in Labcorp Holdings Inc. (NYSE:LH) by 13.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,745 shares of the medical research company’s stock after acquiring an additional 3,395 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Labcorp were worth $7,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Caldwell Trust Co purchased a new stake in Labcorp during the 2nd quarter valued at about $25,000. Financial Gravity Companies Inc. acquired a new stake in shares of Labcorp during the second quarter worth about $26,000. Motco purchased a new stake in Labcorp in the third quarter valued at approximately $32,000. Headlands Technologies LLC lifted its stake in Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 96 shares during the period. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on LH shares. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group reduced their price objective on Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a research note on Wednesday, October 29th. Robert W. Baird raised their target price on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $302.75.

Insider Activity at Labcorp

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total transaction of $25,266.54. Following the completion of the sale, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. The trade was a 3.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 5,273 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the transaction, the chief executive officer owned 87,343 shares in the company, valued at approximately $24,838,602.34. This trade represents a 5.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is currently owned by insiders.

Labcorp Trading Up 0.9%

Shares of NYSE:LH opened at $285.15 on Tuesday. The business’s 50 day moving average price is $265.93 and its 200-day moving average price is $269.49. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a market capitalization of $23.64 billion, a price-to-earnings ratio of 27.26, a price-to-earnings-growth ratio of 1.93 and a beta of 1.03. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The company had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 27.53%.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.